Feasibility, safety and effectiveness of prednisolone and vitamin B1, B6, and B12 in patients with post-COVID-19-syndrome (PreVitaCOV) – protocol of a randomised, double-blind, placebo-controlled multicentre trial in primary care (phase IIIb)

Table 2 Blood and urine tests to be performed at baseline (day 0) and at visit 2 (day 28)

After enrolment in the trial at baseline (Visit 1) - conventional urine pregnancy test (sensitivity down to at least 25mlU/ml for human chorionic gonadotrophin (hCG) for women of childbearing potential - antigen test for SARS-CoV-2 - antibody test for SARS-CoV-2 (anti-nucleocapsid) - glutamate-oxalacetate-transaminase (GOT/ASAT) - glutamate-pyruvate-transaminase (GPT/ALAT) - gamma-glutamyltransferase (GGT) - creatinine and glomerular fitration rate (GFR) - thyroid-stimulating-hormone (TSH) - potassium, sodium, calcium - non-fasting glucose - regular and differential blood count - bilirubin - cortisol-level - vitamin B12 status (homocysteine, methylmalonic acid (MMA), holotranscobalamine) - cytokines
At visit 2 (day 28 + 3) - non-fasting glucose - vitamin B12 status (homocysteine, methylmalonic acid (MMA), holotranscobalamine) - cytokines
Day 32 + 2 - conventional urine pregnancy test (sensitivity down to at least 25mlU/ml for human chorionic gonadotrophin (hCG) for women of childbearing potential

ISSN: 1471-2334